TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: maintain Hb levels within the recommended range 10.0-11.5 g/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean change in Glycosylated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sFlt1/plGF ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Prostate Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects Achieved Acute Procedural Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of Acute Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Sperm DNA integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Area under the insulin aspart curve in the interval from 0-16 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax, maximum insulin aspart concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Device-related Bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Percent decrease in reflux time (RT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Freedom from target vessel deep venous thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Onset time of epidural anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days alive and receiving full enteral feeding
Endpoint domain: Mortality/survival
Primary endpoint: Central Obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: eradication rate of Helicobacter pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Amplitude power of magnetic brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Source location of magnetic brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from perianal fistula disease severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Brief Visuospatial Memory Test-Revised (BVMT-R) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Arabic Verbal Memory Test (VMAT) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Symbol Digit Modalities Test (SDMT) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Stroop test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in physical strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time and frequency of visually detected white spot lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcomes of deep anterior lamellar keratoplasty (DALK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Cortisol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adequate Depression Treatment Response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drug incompatibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced expiratory volume in the first second/forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung diffusion capacity for carbon monoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Short-form 36 questionnaire (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (DEMQOL-proxy)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Allergic Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Performance of the MediGuide™ system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent mammographic density estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: decrease in plasma HCV RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diameter of brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Brachial artery flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Procalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serotype specific capsular antibody formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional antibody formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Skin Irritation Score of the Application Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Morning Pre-dose Trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain-specific event related potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bloodflow pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline of Fluorescein Corneal Staining (FCS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of MACCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in child exposure to tobacco smoke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Normalized Number of GERD Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Management of thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Convenience of Pneumatic Vest
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in FEV1 % Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Expiratory Volume in One Second (FEV1) AUC0-24 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite endpoint of death, myocardial infarction, stroke, urgent coronary revascularization, stent thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Graft loss and/or death with graft function
Endpoint domain: Mortality/survival
Primary endpoint: Stabilization or reduction of diabetic neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participants Adherence to the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of Overeating Episodes Characterized as 'Overeating'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five proportions (%) of dissection findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three diameters (mm) of dissecting arterial segment and contralateral segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wall measurement (mm2) of dissecting arterial segment and contralateral segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe Acute Pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Degree of mitral regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dynamics of heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: At Least One Day With Grade 2 or Higher Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Relationship quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Radiation toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in metabolic tumor volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in total lesion glycolysis values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean visual skin blanching score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes of Number of readable segments (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma tranexamic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physician practice
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Student fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grade 3 & 4 AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Canadian Occupational Performance Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Analogue Scale Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants engaged in smoking cessation counseling
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in CAPS-5 total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adrenal activity in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adrenal activity during stimulation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Kinematic measures of lower extremity and the whole body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinetic measures of lower extremity and the whole body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyographic measures of lower extremity and the whole body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain/discomfort during endometrial biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of men with post-treatment PSA doubling time greater than or equal to 200% pre-treatment PSA doubling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of Trivalent Influenza Vaccine (TIV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient Satisfaction Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Non-liver transplant mortality
Endpoint domain: Mortality/survival
Primary endpoint: local control of skin metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of symptoms of palpitations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Cure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients without AF/AFl/AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Distal Contractile Index (DCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Minimal Residual Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Respiratory mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gas exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change of Sleeping Dysfunction Rating Scale (SDRS) total score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Recurrent Clostridium difficile infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in symptom-limited total exercise duration (TED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Japanese Orthopaedic Association Myelopathy Evaluation Questionnaire (JOACMEQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Modified Japanese Orthopaedic Association Scale (Modified JOA scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Videostyle-mediated intubation skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion in affected shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of BI 638683
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of BI 638683
Endpoint domain: Adverse events/effects
Primary endpoint: Physiological reactivity to food and non-food cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive reactivity to food and non-food cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteogenic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cerebrovascular Reactivity (CVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Morphine Milligram Equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of condom or effective method of birth control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Body Weight (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coughing severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in the HAMD-17 Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shape of airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with Solicited Local Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Solicited Systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Serious Adverse Events (SAE's)
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-dependent Immunogenicity of ExPEC4V on Day 15 (ELISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Long-Term Immunogenicity of ExPEC4V Dose Selected for Further Clinical Development (ELISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Displacement of Subretinal Hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: change of DHEA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change of DHEAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change of testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change of androstenedione
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Force Vital Capacity (FVC) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced expiratory volume in 1 second (FEV1) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Impact of COPD change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Plasma Phe and Tyrosine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful detection of biliary vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cell-free tumor DNA detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adverse events to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline interictal photophobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Healing Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Knee adduction moment during level walking and stair negotiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Medial knee joint contact force during level walking and stair negotiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle co-activation ratio during level walking and stair negotiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Association between patients' characteristics and ICU admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenation indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self rated symptoms of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of comprehensive adverse outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Left ventricular torsion (°)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pictorial memory task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Verbal memory task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pre-transplant peripheral insulin sensitivity and glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio of circulating, gut-homing (alpha4beta7+) Th1 subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of Helios or glycoprotein A repetitions in Tregs versus conventional T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: initial PAED score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rate (CR + CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adequate Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in temporal dynamics of response to emotional anticipation task (fMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in slope measure of diurnal cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in lung function from pre-training to post-training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Yale-Brown Obsessive Compulsive Challenge Scale (YBOCCS) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients with ICU-acquired infection
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response Rate (ORR) at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of dry eye
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Transfusion-transmitted Malaria
Endpoint domain: Adverse events/effects
Primary endpoint: Composite endpoint of investigator global assessment and patient assessment of severity of lateral canthal lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ROC curve for PLTP in the occurrence of GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ROC curve for LPS in the occurrence of GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharged to home
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Step increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Session Attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Skin Testing Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety and tolerability of ABT-333
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters of ABT-333
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in adiposity (% body fat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Qualitative Spleen Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Percentage of Pitted Cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Howell Jolly Body (HJB) Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of Vasospastic Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes